KRAS (IDYLLA KRAS Mutation Test)

General Information

ACCREDITATION STATUS: 

NOT ACCREDITED
Turnaround Time:

For urgent referrals 48hrs

Mutation Spectrum:

Codons 12,13,59,61,117,146

Specimen Requirements:

RAS (KRAS and NRAS) mutations confer resistance to anti-EGFR monoclonal antibodies, and act as a negative predictive marker for these therapies.  The National Institute for Clinical Excellence (NICE) has approved the use of Cetuximab and Panitumumab for the treatment of metastatic colorectal cancer in patients who carry normal, “wild-type” RAS genes. RAS testing is mandatory prior to their prescription.

  • Paraffin block from biopsy, resection or cell block
  • 6μm on unstained mounted slides

Please note tissue handling, tissue fixation, time between cutting and staining and excessive drying can lead to loss of expression. Fixatives containing alcohol should not be used and use of Bouin’s fixative will preclude testing by FISH methods.

A copy of the original Pathology report where possible.

RAS Request Form

General Information

General information about the website and its content

Location of Laboratories

Where the laboratories are located and information about the services offered at each laboratory